Zila Retains William Blair & Company as Its Financial Advisor
October 01 2008 - 1:00PM
Business Wire
Zila, Inc. (NASDAQ:ZILAD) today announced that it has retained
investment bank William Blair & Company to assist it in
exploring strategic business opportunities. �In recent months, we
have established a solid foundation upon which to grow our business
by reducing expenses, restructuring our operations and adding new
international markets for ViziLite� Plus,� said David Bethune,
chairman and chief executive officer of Zila. �The engagement of
William Blair is an important element in our plan to shore up our
capital structure and further evaluate opportunities for growth.�
About Zila, Inc. Zila, Inc., is a fully integrated oral diagnostic
company dedicated to the prevention, detection and treatment of
oral cancer and periodontal disease. ViziLite� Plus with TBlue�,
the company's flagship product for the early detection of oral
abnormalities that could lead to cancer, is the first and only
adjunctive medical device cleared by the FDA for use in a
population at increased risk for oral cancer. In addition, Zila
designs, manufactures and markets a suite of proprietary products
sold exclusively and directly to dental professionals for
periodontal disease, including the Rotadent� Professional Powered
Brush, the Pro-Select Platinum� ultrasonic scaler and a portfolio
of oral pharmaceutical products for both in-office and home-care
use. This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based largely on Zila's expectations
or forecasts of future events, can be affected by inaccurate
assumptions and are subject to various business risks and known and
unknown uncertainties, a number of which are beyond the Company's
control. Therefore, actual results could differ materially from the
forward-looking statements contained herein. A wide variety of
factors could cause or contribute to such differences and could
adversely affect revenue, profitability, cash flows and capital
needs. There can be no assurance that the forward-looking
statements contained in this press release will, in fact, transpire
or prove to be accurate. For a more detailed description of these
and other cautionary factors that may affect Zila's future results,
please refer to Zila's Form 10-K for its fiscal year ended July 31,
2007 and Form 10-Q for the quarter ended April 30, 2008. For more
information about the company and its products, please visit
www.zila.com.
Zila (MM) (NASDAQ:ZILAD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Zila (MM) (NASDAQ:ZILAD)
Historical Stock Chart
From Dec 2023 to Dec 2024